European Journal of Clinical Pharmacology

, Volume 28, Issue 5, pp 553–557 | Cite as

Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram

A double-blind comparison of three dose levels
  • L. Bjerkenstedt
  • L. Flyckt
  • K. Fredricson Overø
  • O. Lingjærde
Originals

Summary

Three dose levels (5, 25, and 50 mg once daily) of the selective serotonin uptake inhibitor citalopram were compared in a four-week, double-blind trial in depressed patients. Serum levels of citalopram and desmethylcitalopram, and the inhibitory effect of serum on serotonin uptake by fresh platelets, were assessed once weekly during the trial. The serum concentrations of citalopram were highly correlated with inhibition of serotonin uptake. Less of the metabolite was found, it being detected only in the higher dose groups. Steady state levels of citalopram, attained after 1 week, were linearly related to dose. The relationship between improvement (percentage reduction in total score on the Montgomery-Åsberg Depression Rating Scale) and serum level of citalopram indicated a lower limit of effect in endogenous depression at about 100 nM, corresponding to an average dose of 15 mg. Marked improvement was seen in ten patients with steady state levels in the range 70 to 335 nM. The ten nonendogenously depressed patients had steady state levels from 15 to 620 nM; complete remission was seen in the three with the lowest levels (15–25 nM). No significant correlation was found between serum drug level and the few reported side effects.

Key words

citalopram serotonin uptake inhibition depressed patients steady state levels clinical effect desmethylcitalopram platelets side-effects dose-response relationship 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Åsberg M, Cronholm B, Sjöqvist F, Tuck D (1970) Correlations of subjective side effects with plasma concentrations of nortriptyline. Br Med J 4: 18–21Google Scholar
  2. Bech P (1984) Citalopram versus clomipramine: a controlled clinical study. Clin Neuropharmacol 7: 876Google Scholar
  3. Bjerkenstedt L, Edman G, Flyckt L, Sedvall G, and Wiesel F (1984) Clinical and biochemical effects of citalopram in depressed patients. Clin Neuropharmacol 7: 874Google Scholar
  4. Bjerkenstedt L, Edman G, Flyckt L, Hagenfeldt L, Sedvall G, Wiesel F (1985) Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor — a dose-response study in depressed patients. Psychopharmacology (in press)Google Scholar
  5. Boeck V, Fredricson Overø K, Svendsen O (1982) Studies on Acute Toxicity and Drug Levels of Citalopram in the Dog. Acta Pharmacol Toxicol 50: 169–174Google Scholar
  6. Boeck V, Jørgensen A, Fredricson Overø K (1984) Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels. Psychopharmacology 82: 275–281Google Scholar
  7. de Wilde J, Mertens C, Fredricson Overø K, Høpfner Petersen HE (1985) Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand (in press)Google Scholar
  8. Fredricson Overø K (1981) Fluorescence assay of citalopram and its metabolites in plasma by scanning densitometry of thin layer chromatograms. J Chromatogr 224: 526–531Google Scholar
  9. Fredricson Overø K (1982a) Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuro-Psychopharmacol Biol Psychiatry 6: 297–309Google Scholar
  10. Fredricson Overø K (1982b) Kinetics of citalopram in man; plasma levels in patients. Prog Neuro-Psychopharmacol Biol Psychiatry 6: 311–318Google Scholar
  11. Gastpar M, Gastpar G (1982) Preliminary studies with citalopram (Lu 10-171), a specific 5-HT reuptake inhibitor, as antidepressant. Prog Neuro-Psychopharmacol Biol Psychiatry 6: 319–325Google Scholar
  12. Gottlieb P, Wandall T, Fredricson Overø K (1980) Initial, clinical trial of a new specific 5-HT reuptake inhibitor, citalopram (Lu 10-171) Acta Psychiatr Scand 62: 236–244Google Scholar
  13. Gurney C, Roth M, Garside RF, Kerr TA, Schapia K (1972) Studies in the classification of affective disorders. The relationship between anxiety state and depressive illnesses. Br J Psychiatry 121: 162–166Google Scholar
  14. Hyttel J (1977) Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology 51: 225–233Google Scholar
  15. Hyttel J (1982) Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol Biol Psychiatry 6: 277–295Google Scholar
  16. Lindegaard Pedersen O, Kragh-Sørensen P, Bjerre M, Fredricson Overø K, Gram LF (1982) Citalopram, a selective serotonin reuptake inhibitor, clinical antidepressive and long-term effect. A phase II study. Psychopharmacology 77: 199–104Google Scholar
  17. Lingjærde O (1984) Platelet serotonin uptake inhibition as a basis for monitoring antidepressant drug treatment. Experiences from a trial with zimelidine and desipramine. J Clin Psychopharmacol 4 (2): 76–81Google Scholar
  18. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389Google Scholar
  19. Øfsti E (1982) Citalopram — a specific 5-HT-reuptake inhibitor — as an antidepressant drug: a phase II multicentre trial. Prog Neuro-Psychopharmacol Biol Psychiatry 6: 327–335Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • L. Bjerkenstedt
    • 1
  • L. Flyckt
    • 1
  • K. Fredricson Overø
    • 2
  • O. Lingjærde
    • 3
  1. 1.Dept. of Psychiatry and PsychologyKarolinska InstituteStockholmSweden
  2. 2.Biochemical DepartmentH. Lundbeck A/SCopenhagenDenmark
  3. 3.Section of Clinical PsychiatryUniversity of TromsøNorway

Personalised recommendations